LSTA

Lisata Therapeutics, Inc. (LSTA) SWOT Analysis Analysis (2026)

Invetso Score: 7.1/10 — Strong · Last Updated: 2026-09-01

Strengths

Strong liquidity with a current ratio of 3.69 and cash ratio of 3.50.

Gross profit margin remains very high at 95%, indicating the core product/service still carries strong unit economics.

Balance sheet leverage appears minimal, with debt-to-equity and debt-to-assets both at 0.

Weaknesses

TTM profitability is deeply negative, with net profit margin at -146.21% and EBIT margin at -160.71%.

Operating efficiency is extremely weak, with asset turnover at 0.01 and working capital turnover at 0.01.

Cash generation is negative, as operating cash flow per share is -1.35 and free cash flow per share is -1.35.

Cost structure is heavily burdened by SG&A at 116.44% of revenue and R&D at 48.81% of revenue.

Opportunities

If revenue scales meaningfully, the high gross margin could support operating leverage.

The company has no debt, which preserves flexibility for financing growth or restructuring if needed.

A current ratio above 3.0 provides near-term runway to execute on a turnaround.

Threats

Persistent losses and negative free cash flow create ongoing going-concern and dilution risk.

Extremely poor cash conversion cycle metrics, including days of sales outstanding at 730 and a negative cash conversion cycle, point to severe working-capital strain.

The valuation remains highly stretched on sales, with EV/sales at 47.65 and price/sales at 152.08 despite negative earnings.

Overall Score

Monthly Update

No material changes this month.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Lisata Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →